Antiphospholipid Antibodies and Fetal Growth Restriction

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified January 2015 by Saint Thomas Hospital, Panama
Information provided by (Responsible Party):
Osvaldo A. Reyes T., Saint Thomas Hospital, Panama Identifier:
First received: February 19, 2012
Last updated: January 1, 2015
Last verified: January 2015
The Antiphospholipid Syndrome is an immune disease where the presence of antibodies directed against cell membrane phospholipids (antiphospholipid antibodies) can cause an hypercoagulable state that causes thrombosis and obstetric complications (miscarriages, stillbirths). Since 1999 the Sapporo Criteria for Antiphospholipid Syndrome diagnosis includes the development of fetal growth restriction (diagnosed postpartum), but this was done without solid evidence of a relation between the two or using the most common form of fetal growth restriction diagnosis (ultrasound). Our study will try to add information to this particular point.

Fetal Growth Restriction
Antiphospholipid Syndrome

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Antiphospholipid Antibodies and Early Fetal Growth Restriction (<34 Weeks of Gestation). A Case Control Study.

Resource links provided by NLM:

Further study details as provided by Saint Thomas Hospital, Panama:

Primary Outcome Measures:
  • Lupus anticoagulant [ Time Frame: 8 months ] [ Designated as safety issue: No ]
    Number of cases positive for Lupus Anticoagulant.

  • Anticardiolipin antibodies [ Time Frame: 10 months ] [ Designated as safety issue: No ]
    Number of cases with high/medium levels of IgG/IgM of anticardiolipin antibodies.

  • B2 Glycoprotein I [ Time Frame: 10 months ] [ Designated as safety issue: No ]
    Number of cases with levels of B2 Glycoprotein I > 99%

Estimated Enrollment: 90
Study Start Date: June 2015
Estimated Study Completion Date: March 2016
Estimated Primary Completion Date: February 2016 (Final data collection date for primary outcome measure)
Patients with ultrasonographic diagnosis of fetal growth restriction.
Patients with normal pregnancies at term.


Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Pregnant patients admitted for fetal growth restriction (cases) and normal patients in labor at term (controls).

Inclusion Criteria:

  • Gestational age between 24-34 weeks.
  • Ultrasonographic evidence of fetal growth restriction

    • Abdominal circumference < 3rd percentile.
    • Doppler with increase of placental resistance.

Exclusion Criteria:

  • Known antiphospholipid syndrome.
  • Known presence of antiphospholipid antibodies.
  • Patients with systemic lupus erythematosus.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01538134

Saint Thomas Maternity Hospital
Panama, Panama
Sponsors and Collaborators
Saint Thomas Hospital, Panama
Principal Investigator: Osvaldo Reyes, MD Saint Thomas Hospital, Panama
  More Information

Responsible Party: Osvaldo A. Reyes T., Coordinator of Research & Development, Saint Thomas Hospital, Panama Identifier: NCT01538134     History of Changes
Other Study ID Numbers: MHST2012-01B 
Study First Received: February 19, 2012
Last Updated: January 1, 2015
Health Authority: Panama: Ministry of Health

Keywords provided by Saint Thomas Hospital, Panama:
Antibodies, anticardiolipin
Antibodies, B2 Glycoprotein I
Lupus Anticoagulant
Fetal Growth Restriction

Additional relevant MeSH terms:
Fetal Diseases
Antiphospholipid Syndrome
Fetal Growth Retardation
Autoimmune Diseases
Growth Disorders
Immune System Diseases
Pathologic Processes
Pregnancy Complications
Antibodies, Antiphospholipid
Immunologic Factors
Physiological Effects of Drugs processed this record on May 22, 2016